炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为曾与华熙生物、爱美客齐名的国内"医美三剑客"之一，昊海生科凭借A+H双融资平台的资本优势及 在医美、眼科等高景气赛道的布局，一度成为市场瞩目的明星企业。 然而眼下，与其昔日光环相伴的，是核心业务增长引擎集体失速，为寻求突围而进行的并购交易疑窦丛 生，公司治理层面问题频发等。 业绩全面失速仍慷慨分红 控股股东成最大受益者 从业绩表现看，公司营收与净利润已连续多个季度同比下滑。2025年前三季度，公司实现营业收入 18.99亿元，同比下降8.47%；实现归母净利润3.05亿元，同比下降10.63%；实现扣非归母净利润2.55亿 元，同比下降20.75%。 结合业务看，营收占比最大的医美板块增长疲态已有所显现。核心产品玻尿酸销售收入上半年仅为3.47 亿元，同比大幅下滑16.8%。尽管公司推出了第四代有机交联玻尿酸等新产品，但在行业整体消费需求 不足、价格竞争日趋白热化以及监管环境变化的背景下，明星产品线增长乏力，短期内难以看到强劲的 复苏拐点。 眼科业务作为公司战略重心则遭遇政策与市场的双重夹击。一方面，2023年11月，业务核心产品人 ...

格隆汇12月23日丨昊海生科(688366.SH)公布，公司控股股东、实际控制人之一蒋伟此前因非本公司事 项，收到中国证监会出具的《行政处罚事先告知书》。近日，公司收到蒋伟告知，获悉其因前述事项， 收到了中国证监会出具的《行政处罚决定书》。行政处罚决定书的主要内容为：因蒋伟内幕交易、建议 他人买卖证券行为，中国证监会决定没收其违法所得4709741.41元，并对其处以14629224.23元罚款。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年12月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 ...

Group 1: Domestic News - Xi Jinping emphasized the responsibilities of central enterprises to better serve the national agenda and contribute to high-quality economic development, urging them to focus on core functions and enhance competitiveness [2] - Premier Li Qiang highlighted the importance of central enterprises in advancing new infrastructure construction and ensuring the self-sufficiency of industrial and supply chains, while also calling for deeper reforms in state-owned enterprises [3] - The National Housing and Urban-Rural Development Conference acknowledged the significant changes in the real estate market and emphasized the potential for further development, advocating for a new model of real estate development that meets public housing needs [4] Group 2: International News - The U.S. GDP for Q3 grew by 4.3%, exceeding expectations of 3.3%, with consumer spending showing strong growth at 3.5%, indicating robust economic expansion despite rising borrowing costs [5] - U.S. durable goods orders fell by 2.2% in October, significantly below the expected decline of 1.5%, although year-on-year growth remained at 4.7%, indicating resilience in manufacturing orders [6] Group 3: Bond Market Dynamics - The bond market showed signs of strength with a notable entry of configuration funds, leading to a decline in yields for 10-year government bonds to 1.8350% and 10-year policy bank bonds to 1.898% [11] - The convertible bond market experienced adjustments, with major indices declining and a majority of individual bonds falling, indicating a mixed performance in the market [17] Group 4: Commodity Market - International crude oil prices continued to rise, with WTI crude up by approximately 0.64% to $58.38 per barrel, and natural gas prices surged over 10% [7] Group 5: Financial Market Operations - The central bank conducted a reverse repurchase operation of 593 billion yuan at a fixed rate of 1.40%, resulting in a net withdrawal of 760 billion yuan due to maturing reverse repos [8] - The funding rates remained low, with DR001 and DR007 declining to 1.269% and 1.411% respectively, indicating a continued loose monetary environment [9]

《科创板日报》12月24日讯，今日科创板早报主要内容有：习近平对中央企业工作作出重要指示；北京 发放首批L3级高速公路自动驾驶车辆专用号牌；第六批国家高价值耗材集采启动；海博思创智造拟投 建20亿元储能工厂项目。 《科创板日报》主播小K为您播报。 商务部：坚决反对美针对无人机领域增列"不可信供应商清单" 商务部新闻发言人就美针对无人机领域增列"不可信供应商清单"事答记者问。有记者问：近日，美国联 邦通信委员会（FCC）发布公告，宣布将所有外国生产的无人机系统及其关键零部件等列入"不可信供 应商清单"（Covered List），请问中方对此有何回应？答：美方以所谓"国家安全"为由，将所有外国生 产的无人机系统及其关键零部件等列入"不可信供应商清单"，中方对此坚决反对。近年来，美方不顾中 美两国企业开展正常商业交易和贸易往来，不顾中美两国业界的强烈呼声，一再泛化国家安全概念，动 用国家力量打击包括中国企业在内的他国企业，这是典型的市场扭曲和单边霸凌做法。中方敦促美方停 止错误做法，立即撤销有关措施。若美方继续一意孤行，中方将坚决采取必要措施，坚定维护中国企业 的正当权益。 北京发放首批L3级高速公路自动驾驶车辆 ...

导读：智通财经12月24日投资避雷针，近日，A股及海外市场潜在风险事件如下。国内经济信息方面包括：1）广期所调整铂等品种相关期货合约交易手续 费标准、涨跌停板幅度和交易保证金标准；2）锡业分会发文，锡价急速拉升已完全背离基本面；公司方面重点关注包括：1）8连板胜通能源表示，如未来 股票价格进一步上涨，可能申请停牌核查；2）2连板利柏特公告，公司不涉及可控核聚变业务；海外市场重点关注包括：1）美国第三季度GDP远超预期， 通胀隐忧仍存；2）日本核反应堆20毫升含放射性水泄漏。 经济信息 1、广州期货交易所公告称，根据《广州期货交易所风险管理办法》，经研究决定，自2025年12月25日交易时起，非期货公司会员或者客户在多晶硅期货 PS2601、PS2602、PS2603、PS2604、PS2605、PS2606、PS2607、PS2608、PS2609、PS2610、PS2611、PS2612合约上单日开仓量分别不得超过200手。 2、广期所公告，经研究决定，对铂、钯、碳酸锂期货相关合约的交易手续费标准、涨跌停板幅度和交易保证金标准作如下调整：自2025年12月25日交易时 起，铂期货PT2606合约、钯期货PD ...

Group 1 - Xi Jinping emphasized the need for central enterprises to focus on their main responsibilities and continuously optimize the layout of state-owned economy, enhancing core functions and competitiveness [1] - The central enterprise leaders' meeting highlighted the importance of providing strong support for major infrastructure construction and accelerating the update and digital transformation of traditional infrastructure [2] - The Ministry of Commerce expressed strong opposition to the U.S. adding foreign-produced drone systems to its "untrusted supplier list" under the guise of national security [4] Group 2 - As of December 23, the total trading volume of A-shares reached 407.82 trillion yuan, marking a nearly 58.4% increase year-on-year and setting a new annual record [8] - Several banks in Shenzhen have raised the minimum interest rate for business loans to 2.35%, reversing a previous trend of lower rates [7] - Semiconductor company SMIC has implemented a price increase of approximately 10% on certain production capacities, with expectations of rapid execution of these increases [10] Group 3 - The sixth batch of national high-value consumables procurement has been initiated, introducing multiple mechanisms to prevent malicious low pricing [9] - Companies such as Zhenyu Technology and Haibo Technology announced significant investments in robotics and green energy storage projects, with planned investments of 10 billion yuan and 20 billion yuan respectively [13]

Policy Developments - The National Healthcare Security Administration is soliciting public opinions on the "Traditional Chinese Medicine Decoction Pieces Traceability Code Encoding Rules" to promote a unified traceability system for traditional Chinese medicine [1] - The National Medical Products Administration has released the "Internet Drug and Medical Device Information Service Filing Management Regulations," which will take effect immediately [2] Drug and Device Approvals - YHLO Biotech announced that it has received medical device registration certificates for two products from the Guangdong and Hunan Provincial Medical Products Administration [3] - Lianhuan Pharmaceutical reported that its raw material drug, Levonorgestrel, has passed pre-certification by the World Health Organization, although this will not significantly impact current operating performance [4] Capital Market Activities - Taiji Group plans to publicly transfer 40% of its stake in the subsidiary company Aida through a public listing, with an initial transfer price of 108,000 yuan [5] - Jiangsu Zhiyuan Pharmaceutical has completed nearly 300 million yuan in Pre-IPO financing, led by Innovation Works [6] Industry Developments - Tongxin Medical announced that its fully magnetic levitation artificial heart has completed enrollment of 100 patients in the INNOVATE clinical trial in the U.S. [7][8] - Novo Nordisk plans to launch the oral version of Wegovy in the U.S. in January 2026, marking it as the first oral GLP-1 drug for weight management [9] Public Sentiment - The Zhejiang Provincial Government has dispatched a working group to oversee the follow-up handling of a medical incident involving a child's postoperative death at Ningbo University Women's and Children's Hospital [10] Regulatory Actions - Haohai Biological Technology announced that its controlling shareholder, Jiang Wei, has been fined 14.63 million yuan by the China Securities Regulatory Commission for insider trading, which will not affect the company's daily operations [11]

Group 1: Real Estate Market - The Ministry of Housing and Urban-Rural Development emphasizes stabilizing the real estate market through city-specific policies to control new supply, reduce inventory, and improve supply quality [2] - The meeting highlights the importance of utilizing existing land through urban renewal and the acquisition of existing commercial housing for affordable housing and other purposes [2] Group 2: Transportation Investment - The Ministry of Transport projects that transportation fixed asset investment will exceed 3.6 trillion yuan this year, with over 2,000 kilometers of new high-speed rail and approximately 8,000 kilometers of new highways [2] - The cross-regional movement of people is expected to surpass 66 billion person-times, with a freight volume exceeding 580 billion tons, both showing a year-on-year growth of around 3.5% [2] Group 3: Company News - Victory Energy - Victory Energy's stock has seen a continuous rise, with a cumulative increase of 114.44% over eight consecutive trading days, leading to potential application for a trading suspension if prices continue to rise [6] - The company clarifies that it does not engage in robotics-related business and remains focused on liquefied natural gas procurement, transportation, and sales [5] Group 4: Company News - Xinghua New Materials - Xinghua New Materials plans to acquire 70% of Dongwang Technology for 140 million yuan, marking its entry into the artificial intelligence and computing power sectors [6] - This acquisition is expected to transform the company’s strategic direction, enhancing its revenue and profitability by tapping into new growth areas [6][7] Group 5: Company News - Other Companies - Oriental Yuhong reports a telecom fraud incident involving approximately 1.7183 million USD, with measures taken to mitigate losses [8] - China Power Construction has signed a contract worth approximately 6.626 billion yuan for the construction of gas booster stations in Turkey [11] - Rongchuang China has completed a comprehensive debt restructuring, significantly reducing its debt pressure by nearly 60 billion yuan [12]

Core Viewpoint - The announcement highlights that the administrative penalty imposed on Jiang Wei, a controlling shareholder and actual controller of Shanghai Haohai Biological Technology Co., Ltd., is related to personal insider trading activities and does not impact the company's operations or finances significantly [1][2]. Group 1: Administrative Penalty Details - Jiang Wei received an administrative penalty from the China Securities Regulatory Commission (CSRC) for insider trading and advising others to trade securities, resulting in a total penalty of 19.34 million yuan, which includes the confiscation of illegal gains of 4.71 million yuan and a fine of 14.63 million yuan [1][3]. - The penalty is solely related to Jiang Wei's personal actions and is not connected to the company's business operations [2]. Group 2: Company Operations and Management - The company confirmed that Jiang Wei does not participate in daily management, and the penalty will not have a significant impact on the company's daily operations, business, or financial status [2]. - As of the announcement date, all production and operational activities of the company are proceeding normally and in an orderly manner [2]. Group 3: Shareholding and Wealth Information - Jiang Wei and his spouse, You Jie, are the controlling shareholders of the company, holding 28.53% and 17.29% of shares, respectively [3]. - According to the 2025 Hurun Global Rich List, the couple's wealth is estimated at 7.3 billion yuan, ranking them 3206th [3]. Group 4: Company Profile - Shanghai Haohai Biological Technology Co., Ltd. is a technology innovation company specializing in the research, production, and sales of medical devices and pharmaceuticals using biomedical materials and genetic engineering technology [3]. - The company is recognized as one of the leading hyaluronic acid producers in China, with a business matrix covering four main categories: hyaluronic acid, epidermal repair gene engineering preparations, and radiofrequency and laser equipment [3].